Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus
Emily Bodnar, an analyst from H.C. Wainwright, has maintained a Buy rating on Agenus with a price target of $23.00. This rating is supported by promising developments in Agenus's clinical trials, particularly a Phase 1b trial showing significant survival benefits in cancer patients. Additionally, a strategic partnership with Zydus is expected to provide financial support for the Phase 3 BATTMAN trial. Recent compassionate use authorization in France further enhances the company's regulatory prospects, justifying the positive outlook.
Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agenus. The associated price target remains the same with $23.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on several promising developments in Agenus’s clinical and regulatory landscape. The company has reported encouraging data from its Phase 1b pan-tumor trial, which demonstrated a significant overall survival benefit in patients with various types of cancer, including those who are refractory to standard treatments. This positive outcome is particularly notable in late-line populations where survival rates are typically lower.
Additionally, Agenus’s strategic partnership with Zydus is expected to provide substantial financial support, facilitating the initiation of the Phase 3 BATTMAN trial. The recent authorization for compassionate use of their treatment in France further underscores the potential for regulatory approval in broader markets. These factors collectively contribute to a favorable outlook for Agenus, justifying the Buy rating.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 5.9% and a 37.02% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Olema Pharmaceuticals, and Atossa Therapeutics.
